Kettering Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Kettering
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Kettering News
The ironic origin story behind Sloan Kettering
Sloan Kettering is one of the world’s leading cancer centers. It was founded by two men who created and sold leaded gasoline — a destructive, carcinogenic poison.
Cancer breakthrough as scientists discover 'switch' that reverses disease
In an astounding breakthrough, scientists have discovered a molecular 'switch' that can revert cancer cells back into healthy cells. It could lead to far less debilitating treatment options.
A personalised vaccine for pancreatic cancer brings ‘hope where none existed before’
Researchers associated with the New York-based Memorial Sloan Kettering Cancer Center have obtained positive results in the Phase 1 clinical trial of an experimental vaccine.
A Vaccine For Pancreatic Cancer Continues To Show Promise
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.

